



162162

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau

WIPO



G00002

(43) International publication date

26 July 2001 (26.07.2001)

PCT

(10) International publication number

WO 01/53256 A1

(51) International patent classification⁷: C07C 279/22,
C07D 233/64, 249/02, A61K 31/41, A61P 9/10

(21) International application number: PCT/EP01/00137

(22) International filing date: 8 January 2001 (08.01.2001)

(25) Language of filing: German

(26) Language of publication: German

(30) Data relating to the priority:
100 01 879.3 19 January 2000 (19.01.2000) DE

(71) Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
[DE/DE]; Brüningstrasse 50, 65929 Frankfurt (DE).

(72) Inventors: WEICHERT, Andreas; Leipziger Strasse 21, 63329
Egelsbach (DE). ALBUS, Udo; Am Römerkastell 9, 61197
Florstadt (DE). JANSEN, Hans-Willi; Distelweg 25, 65527
Niedernhausen (DE). KLEEMANN, Heinz-Werner;
Mainstrasse 29, 65474 Bischofsheim (DE). LANG, Hans-
Jochen; Rüdeshheimer Strasse 7, 65719 Hofheim (DE).

(81) Designated states (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated states (*regional*): ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


- With the International Search Report.

For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.

As printed

(54) Title: SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND A MEDICAMENT CONTAINING THE SAME

(54) Bezeichnung: SUBSTITUIERTE BENZOYLGUANIDINE, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG ALS MEDIKAMENT ODER DIAGNOSTIKUM SOWIE SIE ENTHALTENDES MEDIKAMENT



(57) Abstract: The invention relates to benzoylguanidines of formula (I), wherein R2 stands for -Y-p-(C₆H₄)-R11, -Y-m-(C₆H₄)-R11 or -Y-o-(C₆H₄)-R11; R11 represents (C₁-C₉)-heteroaryl, which is bonded by C or N and is substituted or unsubstituted with 1 to 3 substituents selected from the group consisting of F, Cl, CF₃, CH₃, methoxy, hydroxy, amino, methylamino, dimethylamino and benzyl; Y represents oxygen, -S- or NR₁₂; R12 represents H or (C₁-C₄)-alkyl; R4 F, Cl, Br, I or C₁-C₄-alkyl; R1 and R3 are defined as per the claims. Said benzoylguanidines are suitable for use as anti-arrhythmic medicaments containing cardioprotective components for the prophylaxis and treatment of infarcts and for the treatment of angina pectoris. They also preventively inhibit the

pathophysiological processes associated with the origination of defects caused by ischaemia, in particular during the triggering of ischaemically induced cardiac arrhythmia.

(57) Zusammenfassung: Benzoylguanidine der Formel (I), worin R2 -Y-p-(C₆H₄)-R11, -y-m-(C₆H₄)-R11 oder -Y-o-(C₆H₄)-R11; R11 (C₁-C₉)-Heteroaryl, das über C oder N verknüpft ist und das unsubstituiert oder substituiert ist mit 1 bis 3 Substituenten ausgewählt aus der Gruppe bestehend aus F, Cl, CF₃, CH₃, Methoxy, Hydroxy Amino, Methylamino, Dimethylamino und Benzyl; Y Sauerstoff, -S- oder NR₁₂; R12 H oder (C₁-C₄)-Alkyl; R4 F, Cl, Br, I oder C₁-C₄-Alkyl; R1 und R3 die in den Ansprüchen angegebenen Bedeutungen haben, sind als antiarrhythmische Arzneimittel mit cardioprotektiver Komponente zur Infarktprophylaxe und der Infarktbehandlung sowie zur Behandlung der angina pectoris geeignet. Sie inhibieren auch präventiv die pathophysiologischen Vorgänge beim Entstehen ischämisch induzierter Schäden, insbesondere bei der Auslösung ischämisch induzierter Herzarrhythmien.

WO 01/53256 A1